Literature DB >> 1988254

Omeprazole. Gastrin and gastric endocrine cell data from clinical studies.

R G Berlin1.   

Abstract

Gastric enterochromaffin-like cell carcinoids have been detected in rats exposed lifelong to omeprazole. By inhibiting acid secretion, omeprazole causes hypergastrinemia which, with prolonged exposure, exerts a trophic effect on enterochromaffin-like cells with eventual enterochromaffin-like cell carcinoid formation in some animals. This mechanism seems to explain the appearance of enterochromaffin-like cell carcinoids in human hypergastrinemic states, whether associated with hyperchlorhydria, eg, Zollinger-Ellison syndrome, or with hypochlorhydria, eg, pernicious anemia (nonantral atrophic gastritis). Omeprazole produces modest serum gastrin elevations in humans when monitored over a 24-hr period. Gastrin levels are markedly lower and less sustained than in the above hypergastrinemic states. Extensive gastric biopsy data from patients enrolled in long-term studies indicate that omeprazole administration is not associated with clinically significant changes in the human oxyntic endocrine cell population. Man and rat differ markedly both in their gastrin response to a given level of acid inhibition and in their response to the trophic influence of gastrin on enterochromaffin-like cells. The rat model is a false indicator of risk in man.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988254     DOI: 10.1007/bf01300745

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  53 in total

1.  TECHNICAL NOTE: A SILVER METHOD FOR PARAFFIN SECTIONS OF NEURAL TISSUE.

Authors:  A C SEVIER; B L MUNGER
Journal:  J Neuropathol Exp Neurol       Date:  1965-01       Impact factor: 3.685

2.  Histopathology of gastric carcinoids: a survey of 42 cases.

Authors:  E Wilander; M El-Salhy; P Pitkänen
Journal:  Histopathology       Date:  1984-03       Impact factor: 5.087

Review 3.  Gastric carcinoids and related endocrine growths.

Authors:  E Solcia; C Capella; F Sessa; G Rindi; M Cornaggia; C Riva; L Villani
Journal:  Digestion       Date:  1986       Impact factor: 3.216

4.  Mixed type Zollinger-Ellison syndrome in a florid case of multiple endocrine neoplasia type I. A case report.

Authors:  M Duggan; C Anderson
Journal:  Am J Clin Pathol       Date:  1984-10       Impact factor: 2.493

5.  Effect of single dose of omeprazole on the gastrointestinal peptide response to food.

Authors:  J M Allen; T E Adrian; J Webster; A Howe; S R Bloom
Journal:  Hepatogastroenterology       Date:  1984-02

6.  Effects of omeprazole and ranitidine on gastric acid secretion, blood gastrin levels and [3H]-thymidine incorporation in the oxyntic mucosa from dogs and rats.

Authors:  B Ryberg; H Mattsson; E Carlsson
Journal:  Digestion       Date:  1988       Impact factor: 3.216

7.  Low dose omeprazole effects on gastric acid secretion in normal man.

Authors:  P Hemery; J P Galmiche; C Roze; J P Isal; S Bruley des Varannes; A Lavignolle; L Le Bodic
Journal:  Gastroenterol Clin Biol       Date:  1987-02

8.  Achylia and the development of gastric carcinoids.

Authors:  E Wilander
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

9.  The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy.

Authors:  J A Carney; V L Go; V F Fairbanks; S B Moore; E C Alport; F E Nora
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

10.  Effect of intermittent weekend therapy with omeprazole on basal and bombesin- and pentagastrin-stimulated gastric acid and serum gastrin.

Authors:  L F Crobach; J B Jansen; C B Lamers
Journal:  Scand J Gastroenterol       Date:  1988-05       Impact factor: 2.423

View more
  10 in total

1.  Omeprazole: gastrin and gastric data.

Authors:  K G Wormsley
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

Review 2.  Acid suppression and claims of genotoxicity. What have we learned?

Authors:  R A Goodlad
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 3.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

4.  Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.

Authors:  K Jaskiewicz; J A Louw; I N Marks
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

5.  Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment.

Authors:  G Cadiot; T Lehy; P Ruszniewski; S Bonfils; M Mignon
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

Review 6.  Pathophysiological effects of long-term acid suppression in man.

Authors:  R F McCloy; R Arnold; K D Bardhan; D Cattan; E Klinkenberg-Knol; P N Maton; R H Riddell; P Sipponen; A Walan
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

7.  Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis.

Authors:  S Cucchiara; R Minella; C Iervolino; M T Franco; A Campanozzi; M Franceschi; F D'Armiento; S Auricchio
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

8.  An Unusual Case of Multiple Gastric Carcinoids Associated with Diffuse Endocrine Cell Hyperplasia and Parietal Cell Hypertrophy.

Authors:  Akishi Ooi; Masako Ota; Shogo Katsuda; Isao Nakanishi; Hiroyuki Sugawara; Ichiro Takahashi
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

9.  Accelerated gastric epithelial proliferation.

Authors:  M R Gray; S J Darnton; J A Hunt; R W Irlam; J Nemeth; H M Wallace
Journal:  Gut       Date:  1995-04       Impact factor: 23.059

10.  Effect of gastric secretion on penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into gastric mucosa of rats.

Authors:  K K Ovrebø; H Sørbye; S Kvinnsland; K Grong; K Svanes
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.